And payers, especially employers, must revisit total cost-of-care frameworks that balance the one-time cost of surgery against the long-term expense of chronic pharmaceutical management, particularly given fiduciary duties introduced by CMSs Transparency in Coverage initiative
Metabolic syndrome, characterized by a collection of metabolic disorders such as abdominal adiposity, dyslipidemia, hypertension and increased fasting blood glucose, is closely associated with the development of CVDs (Shi et al., 2023)
Monitoring focuses on glucose handling, IGF-axis context, cardiovascular risk, and symptoms that may suggest excessive pathway activity
10.1523/jneurosci.0587-12.2012 J
K., Kanikarla-Marie, P., Warden, C